Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Royalty Pharma PLC (RPRX)
NASDAQ:RPRX
Holding RPRX?
Track your performance easily
Earnings Data
Report Date
Feb 12, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
0.95Last Year’s EPS
1.15Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 10, 2020
|% Change Since: 13.33%
|Next Earnings Date:Aug 12, 2020
Earnings Call Sentiment|Positive
The earnings call highlighted Royalty Pharma's robust financial performance, strategic portfolio expansion, and record capital deployment, although there were challenges with high comparison bases and increasing interest payments. The focus on innovative funding solutions like synthetic royalties suggests a strong future outlook.Company Guidance
During the Royalty Pharma Q3 2024 earnings call, the company reported a robust performance, highlighted by a 15% growth in both portfolio receipts and royalty receipts. The company raised its full-year guidance, now expecting portfolio receipts between $2.75 billion and $2.8 billion, with royalty receipts growth revised to 11% to 13%, up from the previous 9% to 12% guidance. Capital deployment for the year stands at approximately $2.6 billion, including $95 million in share repurchases during the quarter. The company has announced transactions worth $10.1 billion since 2022, deploying $7 billion in capital to date. Royalty Pharma maintains a strong financial position with $950 million in cash and investment-grade debt of $7.8 billion, boasting a weighted average debt cost of 3.1% and an average maturity of 12 years.Strong Financial Performance
Royalty Pharma delivered 15% growth in portfolio receipts and royalty receipts in Q3 2024, raising full-year guidance for portfolio receipts to $2.75 billion to $2.8 billion.
Successful Portfolio Expansion
Acquired royalties on three novel therapies, including FDA approvals for Covent fee in schizophrenia, Verengo in Glioma, and Tremfya in ulcerative colitis.
Record Capital Deployment
Year-to-date capital deployment stands at approximately $2.6 billion, with $95 million in shares repurchased in Q3 as part of a balanced capital allocation strategy.
Innovative Synthetic Royalty Transactions
Announced synthetic royalty transactions valued at $800 million in 2024, marking a record year and demonstrating the attractiveness of this funding modality.
---
RPRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
RPRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 06, 2024 | $27.31 | $26.42 | -3.26% |
| Aug 08, 2024 | $26.82 | $25.74 | -4.03% |
| May 09, 2024 | $27.34 | $27.32 | -0.07% |
| Feb 15, 2024 | $28.42 | $29.34 | +3.24% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Royalty Pharma PLC (RPRX) report earnings?
Royalty Pharma PLC (RPRX) is schdueled to report earning on Feb 12, 2025, TBA Not Confirmed.
What is Royalty Pharma PLC (RPRX) earnings time?
Royalty Pharma PLC (RPRX) earnings time is at Feb 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RPRX EPS forecast?
RPRX EPS forecast for the fiscal quarter 2024 (Q4) is 0.95.
---